CONCLUSION
•Greater uniformity of the assays is needed in order to reduce these discrepancies and enable a correct therapeutic management.
•Management of acromegalic patients with discordant GH -IGF-1 values needs to be individualized and long-term studies on morbidity and mortality are needed.
DISCUSSIONS
• Elevated IGF-1 despite normal GH levels have been described in adolescence, pregnancy, hyperthyroidism, hepatic or renal insufficiency (excluded in our patients), early postoperative period or mild active acromegaly. There are controversies regarding obesity as a contributing factor (42% of patients were obese, 42% were overweight). The long-term evolution in acromegalic patients with GH-IGF-1 discordance and the indication for treatment are not well established. 1 
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